Shanghai Junshi Biosciences Details Board and Committee Structure

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.

Shanghai Junshi Biosciences Co., Ltd. has announced the current composition of its board of directors, which includes a mix of executive, non-executive and independent non-executive directors, led by chairman and legal representative Xiong Jun. The leadership team features roles such as vice chairman, co-chief executive officers and other senior executives, reflecting a broad governance structure for the biotech company.

The board has also detailed the membership of its five key committees: audit, nomination, remuneration and appraisal, strategic and ESG, and compliance. By clarifying chairmanships and memberships across these committees, the company reinforces its corporate governance framework and oversight mechanisms, which may strengthen stakeholder confidence in its internal controls and strategic direction.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in mainland China, listed in Hong Kong under stock code 1877. The company focuses on the research, development and commercialization of innovative medicines, positioning itself within China’s rapidly growing biotech and life sciences sector.

Average Trading Volume: 3,152,085

Technical Sentiment Signal: Sell

Current Market Cap: HK$32.33B

For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.